Competition is critical for the healthcare industry. Biosimilars could offer significant cost savings and enhanced consumer choice. However, it is argued that disparagement of biosimilars could foster negative misconceptions, cause confusion, and discourage their uptake. This panel will discuss whether disparagement could potentially violate antitrust law as well as consumer protection laws.
WilmerHale's Holly Ovington will moderate this ABA Antitrust Section panel discussion on disparagement of biosimilars.
